Thursday, July 01, 2021 11:12:09 AM
New quarter lots of catalysts lined up there is just a sliver of retail shares available. If you been watching this trade they have been trying very hard to scare retail and add to the golden stash. Know what you own. Don’t get robbed for your shares. PDSB was down at these levels 2.00 range near 30% down year to date and then out of now where the stock surged almost 600% don’t be a pole smoker and get robbed for your shares!! You will never recover from owning a stock that’ jumps 500% to a 1000% after you sold for a loss of got your stopped taken out. If you can’t handle a little volatility don’t look at the stock for a few months and you will be see a big lift off from these levels. My money is here and I will keep adding at these levels. No brainer! Remember ARKO and MDGL have inferior Nash drugs and have 1.6 and 1.1 billion market caps HEPA 150 million market cap 115 million in cash with their drug at CRV431 at 75mg is showing efficacy at 28 days what’s MDGL has taken 3 months put your big boy pants and enjoy the ride! FDA already gave the go ahead for 2B in the coming months the higher mgs data is coming the sophisticated AI powr platform is key here.
These crooked MM have been loading huge on the bid and selling small lots all week wake up to scare retail.
This stock is going to go parabolic with or without you. Book it!
$HEPA
Recent HEPA News
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 02:02:26 PM
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:57 PM
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 • GlobeNewswire Inc. • 01/03/2024 10:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:24 PM
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat • GlobeNewswire Inc. • 11/10/2023 01:50:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/09/2023 05:15:08 AM
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules • GlobeNewswire Inc. • 09/29/2023 12:00:00 PM
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/21/2023 08:05:00 PM
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer • GlobeNewswire Inc. • 09/19/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 12:00:24 PM
- Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis • GlobeNewswire Inc. • 09/14/2023 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:40:33 PM
- Hepion Pharmaceuticals Announces Management Changes • GlobeNewswire Inc. • 09/06/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:41:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 08:39:46 PM
- Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 • GlobeNewswire Inc. • 06/15/2023 08:45:00 PM
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat • GlobeNewswire Inc. • 06/15/2023 12:22:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM